Navigation Links
HeartWare Completes GLP Studies of Next Generation MVAD® Pump; Data Presented Today at ISRBP Congress
Date:9/9/2011

AD Pump, and also the breadth of HVAD System adoption outside the United States."

About HeartWare International

HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® Pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.

Forward-Looking Statements

This announcement contains forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.  All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to the timing and progress of, and presentation of data related to, clinical and preclinical trials, expected timing of regulatory f
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. HeartWare to Report 2010 Fourth Quarter and Year-End Financial Results
2. HeartWare to Present at the 22nd Annual Piper Jaffray Health Care Conference
3. HeartWare International, Inc. Temporary Suspension of Trading
4. U.S. Federal Trade Commission to Challenge Thoratecs Proposed Acquisition of HeartWare International
5. Enterologics Completes Acquisition of BioBalance Corp and Probiotic Product From New York Health Care, Inc
6. TWi Biotechnology Successfully Completes Patient Recruitment for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes
7. Kuros Completes Patient Recruitment in a Phase IIb Clinical Trial With KUR-211 for Diabetic Foot Ulcers
8. AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API
9. Peloton Therapeutics Completes $18 Million Series A Financing
10. Sinapis Pharma Completes Phase I Trial
11. MiMedx Group Completes $5,000,000 Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
(Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
(Date:1/14/2014)... 2014 Independent publisher Bitingduck Press, with ... Canada, has big ideas for 2014 in production and ... are to produce high-quality, low-cost, DRM-free ebooks and to ... , The first major development will be bookstore ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... doubled Hectorol sales , Middleton, Wis. Bone ... the work of University of Wisconsin-Madison professor Hector DeLuca, reported ... said its sales of the drug Hectorol were $19.6 million, ... million, despite large theft , Neenah, Wis. ...
... Actor Michael J. Fox plans to visit the Waisman ... Jim Doyle and Fox will hold a media event ... for biotechnology research in Wisconsin. , ,In November, Doyle ... biotechnology and stem cell research, including a collective $750 ...
... wrote about the importance of transparency, which I described ... and maybe even personal perspectives" so that "intelligent consumers ... and write." , ,This transparency puts content in context, ... where the rules of reportorial journalism, more often than ...
Cached Biology Technology:Michael J. Fox coming to UW Waisman Center 2Corporations and blogging 2Corporations and blogging 3
(Date:4/23/2014)... This news release is available in French ... , Montreal, 23 April 2014Today, the CEC released ... A Binational Collaborative Approach to Conservation, which identifies 29 ... States-Mexico border that includes 11 different protected areas in ... features unique, highly diverse arid and semi-arid habitats inhabited ...
(Date:4/23/2014)... NY. (Apr. 23, 2014) People who have had ... to restore neurological function. However, a study conducted in ... of Cell Transplantation , but is currently freely ... http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1168Chen , has found that when one group of ... (PBSCs) injected directly into the brain and a similar ...
(Date:4/23/2014)... in Buenos Aires yesterday, Argentina joins the European ... state. The move strengthens the ties between the ... grants Argentinian scientists access to EMBL,s world-class facilities ... "Ever since its inception, fostering excellent life science ... the core of EMBL,s mission," says EMBL Director ...
Breaking Biology News(10 mins):Conservation priorities released for several protected areas along US-Mexico border 2Conservation priorities released for several protected areas along US-Mexico border 3Autologous stem cell therapy improves motor function in chronic stroke victims 2
... new protein produced excessively in malignant melanoma, a discovery ... dramatically among young women. The protein, IMP-3, is ... the most dangerous types of skin cancer, and in ... predict called thin melanomas. The finding offers a potential ...
... DAGAN, ISRAEL - Table grapes are subject to serious water ... vine to dinner tables around the world. Mold and browning ... grape quality during shipping and storage in retail produce sections. ... one way of ensuring that consumers get fresh, appealing fruits. ...
... Washington, DCMay 28, 2008The 2008 American Society ... the Year Award is presented to Vctor ... of Biotechnology of the Spanish Research Council, ... microbiologist who has exhibited exemplary leadership in ...
Cached Biology News:As rates rise, researchers find better way to identify melanoma 2As rates rise, researchers find better way to identify melanoma 3Fresh from the grapevine to the table 2American Society for Microbiology honors Victor de Lorenzo 2
Tan solid. A glycoside used to permeabilize cellular membranes. Exhibits hemolytic activity. Contaminants: ash: ≤10%. Soluble in H 2 O. pH 4.4 - 4.6. RTECS VQ1400000, CAS 8047-15-2. References:...
...
...
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
Biology Products: